SUBJECT INDEX 



421 



Newborn, 



injection with homologous cells, 



293-327 

 number of lymphocytes in spleen, 



compared with adult, 152 

 rate of immunization, 157 

 Nitrogen, in antigen, 1 1 



Ovarian homograft, 5 



Parabiosis, 406 



autograft rejection in, 349 

 chimerism in, 3 3 7-3 3 9 

 graft-versus-host reaction in, 330 

 induction of tolerance by, 328-349 

 immune status following break- 

 down, 335-336, 339 

 increase due to preimmunization, 



336-337, 340 

 results, 329-331 

 specificity and degree, 333-335 

 Parabiosis intoxication, 329 

 Parabiotic disease, 327, 330, 331, 333, 



335, 336, 341, 383 

 Paralysis, relation with tolerance, 155- 



160 

 Placenta, antigenic inferiority of, 122 

 antigenicity of, 130, 131 

 erythrocytes crossing, 131 

 immunological barrier in, 1 19-120, 



122, 127, 131, 132, 133-135 

 inducing transplantation immunity, 



120-124 

 stimulating immune response, 129 

 Polyvinylpyrrohdone test, 72-73 

 Pregnancy, development of tolerance 

 during, 119, 124, 133, 135-136 

 effect on resistance to tumours, 124 

 effect on skin graft survival, 119, 



124-127, 129, 133 

 immunological reactivity in, 119 

 Preimmunization, and induction of 

 tolerance, 206, 336-337, 340 



Preimmunization, 

 with spleen cells, 190 

 with transplantation antigens, 186, 



187 _ 

 Protein, in antigen, 11 

 in H-2 antigens, 55, 59 



QuaHtative hypothesis ", 138 

 "Quantitative hypothesis", 138, 145 



Radiation chimeras, cell changes in, 

 139 



loss of strain-specificity in tumour 

 transplantation, 175-178 



secondary recipients, 375 



tumour metastasis produced in, 

 164-169 



tumour transplantation in, 163-184 

 Rat, blood groups in, 24 



histocompatibihty loci in, 24 

 Red cell, and transplantation im- 

 munity, 38-39 

 Red cell antigens, 22, 24, 42 

 Red cells, crossing placenta, 131 



sex antigen in, 39-40 



tolerance production with, 40-41 

 Rh incompatibility, 124, 131 

 Ribonucleic acid, in antigen, 11 

 Runt disease, 236 



antigenic strength in, 343 



as function of cell dosage, 242-246, 



255 

 cause of death in, 326-327 

 chronology of, 304-305, 321 

 compared with parabiotic disease, 



330 

 due to injection of lymph node 



cells, 379-380 

 due to injection of lymphocytes, 

 240-241 



chimerism among survivors, 

 252-253, 265, 268, 269 



effects of dose, 160 



in hybrids, 253-254, 255, 257-258 



